This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Farnesyl diphosphate synthase (FDPS; FPPS)	<i>In vitro</i> studies identified non-bisphosphonate FPPS inhibitors that may help treat soft-tissue cancers. <i>In vitro</i> , the most potent non-bisphosphonate compound inhibited FPPS with an IC ₅₀ value of 80 nM. Next steps include compound optimization and proof-of-concept testing in animal models. SciBX 3(34); doi:10.1038/scibx.2010.1035 Published online Sept. 2, 2010	Patent and licensing status undisclosed	Jahnke, W. <i>et al. Nat. Chem. Biol.</i> ; published online Aug. 15, 2010; doi:10.1038/nchembio.421 Contact: Wolfgang Jahnke, Novartis Institutes for Biomedical Research, Basel, Switzerland e-mail: wolfgang.jahnke@novartis.com